Gilead Sciences (GILD) Revenue (2008 - 2026)
Gilead Sciences (GILD) revenue from Jun 30, 2008 to Mar 31, 2026. The TTM Gilead Sciences (GILD) revenue is $30B. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual Revenue
Quarterly Revenue
Gilead Sciences (GILD) Revenue CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | +3.48% |
| 3 Years TTM | +3.21% |
| 5 Years TTM | +3.07% |
| 10 Years TTM | -0.99% |
| All Time TTM | +11.86% |
Annual Revenue change of Gilead Sciences (GILD)
| Year | Revenue | Change |
|---|---|---|
| 2026 | $6.96B | -76.36% |
| 2025 | $29B | +2.40% |
| 2024 | $29B | +6.04% |
| 2023 | $27B | -0.60% |
| 2022 | $27B | -0.09% |
| 2021 | $27B | +10.60% |
| 2020 | $25B | +9.98% |
| 2019 | $22B | +1.46% |
| 2018 | $22B | -15.24% |
| 2017 | $26B | -14.09% |
| 2016 | $30B | -6.89% |
| 2015 | $33B | +31.13% |
| 2014 | $25B | +122.19% |
| 2013 | $11B | +15.46% |
| 2012 | $9.70B | +15.70% |
| 2011 | $8.39B | +5.48% |
| 2010 | $7.95B | +13.38% |
| 2009 | $7.01B | +31.40% |
| 2008 | $5.34B | +26.14% |
| 2007 | $4.23B | N/A |
Comparison Gilead Sciences (GILD) five years revenue CAGR with competitors
Gilead Sciences (GILD) five years revenue CAGR is 3.07%.
| Ticker | Name | five years Revenue CAGR | Upside |
|---|---|---|---|
| LLY | Lilly(Eli) & Company | 23.17% | +654.83% |
| NVO | Novo Nordisk | 20.75% | +575.90% |
| AZN | Astrazeneca plc | 16.99% | +453.37% |
| MRK | Merck & Co Inc | 10.41% | +239.06% |
| AMGN | AMGEN Inc | 8.14% | +165.28% |
| PFE | Pfizer Inc | 6.56% | +113.68% |
| GRFS | Grifols SA | 5.39% | +75.73% |
| SNY | Sanofi | 5.03% | +63.79% |
| ABBV | Abbvie Inc | 4.59% | +49.50% |
| JNJ | Johnson & Johnson | 2.73% | -11.01% |
| BMY | Bristol-Myers Squibb Company | 2.52% | -17.92% |
| NVS | Novartis AG | 2.36% | -23.14% |
| GSK | GSK Plc | 0.63% | -79.40% |